AWARDDEFINITIVE CONTRACTOther than small business
Definitive contract HHSN272200900060CJANSSEN VACCINES & PREVENTION B.V.
Overview
Award facts
- Net obligations
- $48.59M
- $48,585,370of $100.96M potential value
- Period of performance
- Sep 15, 2017 to Aug 14, 2014
- Ended
- Modifications
- 11
- Latest action Sep 15, 2017
- Contract type
- Definitive contract
- PIID HHSN272200900060C
Description of requirement
BIOMEDICAL (BASIC)
Dates and value
- Award date
- Signed on Aug 15, 2009
- Potential end of performance
- Aug 13, 2014
- Current value
- $79,361,174Base and exercised options
- Potential value (if all options are exercised)
- $100,958,063
Obligations by fiscal year of action
- FY2017: -$7,805,323 (de-obligation)
- FY2014: -$6,188,104 (de-obligation)
- FY2013: $13,677,248
- FY2012: $8,118,206
- FY2010: $27,536,741
- FY2009: $13,246,602
Total across 6 fiscal years: $48,585,370
Net de-obligation in that fiscal year (obligations withdrawn).
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Sep 15, 2017. View on USAspending · Recipient on SAM.gov
Recipient
LocationLEIDEN, NLD
UEIVRE2EKNJTJJ4
Business sizeOther than small businessSize at award, per the contracting officer
Parent companyJOHNSON & JOHNSON HEALTHCARE
Business types and certifications
Foreign-ownedFor-profit organizationInternational organization
As represented in SAM.gov at the time of the action.
Subcontracting network
The prime, the subcontractors on this award, and their own subcontractors.
Agency and place
Awarding and funding
- Awarded by
- Department of Health and Human Services
- National Institutes Of Health
- NATIONAL INSTITUTES OF HEALTH NIAID
- Funded by
- Department of Health and Human Services
- National Institutes Of Health
- NATIONAL INSTITUTES OF HEALTH NIAID
- Funded from
- 075-0885Federal accounts (agency financial reports)
Place of performance
- Place of performance
- Netherlands
Classification and competition
Classification
- Product or service (PSC)
- AN11R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH) (research and development)
Competition
- Extent competed
- Full and open competitionA
- Solicitation procedures
- Basic researchBR
- Set-aside
- No set-aside used
- Contract pricing
- Cost plus fixed feeU
- Offers received
- 35
Contract details
- Subcontracting plan
- Plan not requiredB
- Major program
- Application of platform technologies for the development of therapeutics for biodefense
- Cost Accounting Standards clause
- Yes - CAS clause includedY
- Commercial procedures
- Commercial item procedures not usedD
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not a bundled requirementD
- Consolidated requirement
- No
- Undefinitized action (terms not final)
- No
- Multi-year contract
- No
- Performance-based service acquisition
- No - service where PBA is not used.N
Linked notices
Notice | Notice ID | Type | Link | Posted |
|---|---|---|---|---|
Transaction history
Modification history
- Base award
- Aug 15, 2009Base obligation at award: $13,246,602
- Latest action
- Sep 15, 2017 — Funding onlyModification 11; obligation change -$7,805,323; funding only: changes obligations, not scope
- Latest substantive action
- Sep 13, 2013 — Option exercisedModification 8; obligation change +$10,786,489
- Latest funding action
- Sep 15, 2017 — Funding onlyModification 11; obligation change -$7,805,323; funding only: changes obligations, not scope
- Actions by type
- Base award1
- Funding only6
- Option exercised2
- Other administrative action2
- Supplemental agreement (within scope)1
Similar awards
PIID | Match | Awardee |
|---|---|---|
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Synopsized publicly (SAM.gov / FedBizOpps)
- Yes
- A-76 (FAIR Act) action
- No
Pricing and financing
- Paid by purchase card
- No
- Latest action: change in base and exercised options
- -$7,805,323
- Latest action: change in base and all options
- -$7,805,323
Socio-economic and policy
- Recovered materials and sustainability
- No clauses included and no sustainability includedC
- EPA-designated product
- Not requiredE
- Clinger-Cohen Act planning (IT)
- No
Place and origin
- Domestic or foreign entity
- Foreign-owned business incorporated in the U.S.C
- Country of product or service origin
- NetherlandsNLD
- Place of manufacture
- Not a manufactured end productC
Structure
- Award or IDV
- Award
- Award type
- Definitive contractD
- Awarding agency code
- 7500
- Awarding sub-tier code
- 7529
- Contracting office code
- 75N930
- Transactions recorded under this award key
- 12
Funding
- Funding agency code
- 7500
- Funding sub-tier code
- 7529
- Funding office code
- 75N930
- Treasury accounts
- 075-2013/2013-0885-000
- Object classes
- 25.5: Research and development contracts